Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure

Jie LU; Dingchun LI; Ye LIU; Linna YUAN; Zhiwen DUAN; Wu LI

doi:10.3969/j.issn.1001-5256.2022.11.017

Volume 38 Issue 11

Nov. 2022

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(11): 2526-2531

PDF( 1882 KB)

Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.11.017

Department of Infection and Liver Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China

Research funding:

National Natural Science Foundation of China (82160801);

Yunnan Province Famous Doctor Project (Yunrenweifa (2020)20, RLMY20200015);

Yunnan Provincial Department of Science and Technology -Applied Basic Research Joint Special Fund Project (2018FE001 (-214))

More Information

Corresponding author: LI Wu, liwukm@qq.com(ORCID: 0000-0002-1222-3629)
Received Date: 2022-04-25
Accepted Date: 2022-06-20
Published Date: 2022-11-20

Abstract

Abstract

Objective To investigate the clinical efficacy of low-dose plasma exchange (PE) combined with artificial liver in the treatment of acute-on-chronic liver failure (ACLF) and its effect on mortality rate after stratification. Methods A total of 272 ACLF patients who were admitted to Department of Infection and Hepatology, The First Affiliated Hospital of Kunming Medical University, from January 2018 to December 2020 were enrolled and divided into low-dose PE+double plasma molecular absorption system (DPMAS)/hemoperfusion (HP) group (n=190) and medical treatment group(n=82). Laboratory markers were collected before and after treatment, and clinical outcome was compared between the two groups; stratified analysis (early stage, early-middle stage, late stage or types A, B, C) was performed for the two groups according to Diagnostic and treatment guidelines for liver failure (2018 edition), and all patients were followed up to observe general status and death at 12 weeks (short-term) and 48 weeks (long-term) after discharge. The independent samples t-test was used for comparison of normally distributed continuous data between two groups, and the paired samples t-test was used for comparison before and after treatment; the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Wilcoxon test was used for comparison before and after treatment; the chi-square test was used for comparison of categorical data between groups. Results Both low-dose PE combined with DPMAS/HP and medical treatment alone could reduce the levels of alanine aminotransferase (ALT), aspartate aminotransferase, total bilirubin (TBil), and blood ammonia and increase the level of albumin (Alb), and both groups had significant changes in these indices after treatment (all P < 0.05). Compared with medical treatment alone, low-dose PE combined with DPMAS/HP better reduced ALT, TBil, and blood ammonia and improved Alb, with significant changes in these indices after treatment (all P < 0.05). Low-dose PE combined with DPMAS/HP could significantly reduce bile acid, international normalized ratio, neutrophil-lymphocyte ratio, and MELD score and increase platelet-to-white blood cell ratio (all P < 0.05), while medical treatment alone could not improve the above indices (all P > 0.05). Compared with medical treatment alone, low-dose PE combined with DPMAS/HP could reduce the short-term mortality rate of ACLF patients, especially the short-term mortality rate of ACLF patients with early-stage, early-middle-stage or type A ACLF, and there were significant differences between the two groups (all P < 0.05). In the low-dose PE+DPMAS/HP group, the patients with early-stage ACLF had significantly lower short- and long-term mortality rates than those with late-stage ACLF, and the patients with type A ACLF had significantly lower short- and long-term mortality rates than those with type C ACLF (all P < 0.05). Conclusion Low-dose PE combined with DPMAS/HP has good clinical efficacy and can effectively reduce the short-term mortality rate of ACLF, especially the short-term mortality rate of patients with early-stage, early-middle-stage, or type A ACLF.
- Acute-On-Chronic Liver Failure,
- Plasma Exchange,
- Liver, Artificial,
- Treatment Outcome

FullText(HTML)

References(20)

References

[1]	HERNAEZ R, SOLÀ E, MOREAU R, et al. Acute-on-chronic liver failure: an update[J]. Gut, 2017, 66(3): 541-553. DOI: 10.1136/gutjnl-2016-312670.
[2]	ZHANG XL. Clinical study of combined non-biological artificial liver technology in the treatment of liver failure under the condition of blood stress[D]. Kunming: Kunming Medical University, 2018. 张秀灵. 血源紧张条件下组合型非生物人工肝技术治疗肝衰竭的临床研究[D]. 昆明: 昆明医科大学, 2018.
[3]	ZHANG XL, DUAN ZW, YANG RD, et al. Clinical study of plasma exchange combined with dual plasma molecular adsorption system in the treatment of patients with early and mid-stage liver failure under the condition of blood stress[J]. J Prac Hepatol, 2019, 22(2): 289-290. DOI: 10.3969/j.issn.1672-5069.2019.02.034. 张秀灵, 段志文, 杨瑞东, 等. 血源紧张条件下血浆置换联合双重血浆分子吸附系统治疗早中期肝衰竭患者临床研究[J]. 实用肝脏病杂志, 2019, 22(2): 289-290. DOI: 10.3969/j.issn.1672-5069.2019.02.034.
[4]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35(1): 38-44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
[5]	Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on clinical application of artificial liver and blood purification (2022 edition)[J]. J Clin Hepatol, 2022, 38(4): 767-775. DOI: 10.3969/j.issn.1001-5256.2022.04.007. 中华医学会肝病学分会重型肝病与人工肝学组. 人工肝血液净化技术临床应用专家共识(2022年版)[J]. 临床肝胆病杂志, 2022, 38(4): 767-775 DOI: 10.3969/j.issn.1001-5256.2022.04.007.
[6]	FAN Q, LI Z, Liver transplantation for chronic acute liver failure[J]. Qgran Transplant, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008. 范祺, 李照. 慢加急性肝衰竭的肝移植治疗[J]. 器官移植, 2022, 13(3): 333-337. DOI: 10.3969/j.issn.1674-7445.2022.03.008.
[7]	SUN KY, MAO JX, LIU Y, et al. Influencing factors of curative effect of plasma exchange in patients with HBV-related acute-on-chronic liver failure waiting for liver transplantation[J/CD]. Chin J Hepat Surg(Electronic Edition), 2022, 11(3): 252-257. DOI: 10.3877/cma.j.issn.2095-3232.2022.03.008. 孙克彦, 毛家玺, 刘业, 等. HBV相关性慢加急性肝衰竭等待肝移植患者血浆置换疗效影响因素[J/CD]. 中华肝脏外科手术学电子杂志, 2022, 11(3): 252-257. DOI: 10.3877/cma.j.issn.2095-3232.2022.03.008.
[8]	LARSEN FS, SCHMIDT LE, BERNSMEIER C, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial[J]. J Hepatol, 2016, 64(1): 69-78. DOI: 10.1016/j.jhep.2015.08.018.
[9]	YUAN S, QIAN Y, TAN D, et al. Therapeutic plasma exchange: A prospective randomized trial to evaluate 2 strategies in patients with liver failure[J]. Transfus Apher Sci, 2018, 57(2): 253-258. DOI: 10.1016/j.transci.2018.02.001.
[10]	BJURSTEN LM, RASMUSSON L, OH S, et al. Titanium dioxide nanotubes enhance bone bonding in vivo[J]. J Biomed Mater Res A, 2010, 92(3): 1218-1224. DOI: 10.1002/jbm.a.32463.
[11]	YAO J, LI S, ZHOU L, et al. Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on- chronic liver failure[J]. J Clin Apher, 2019, 34(4): 392-398. DOI: 10.1002/jca.21690.
[12]	SUN J, GUO H, YU X, et al. A neutrophil-to-lymphocyte ratio-based prognostic model to predict mortality in patients with HBV-related acute-on-chronic liver failure[J]. BMC Gastroenterol, 2021, 21(1): 422. DOI: 10.1186/s12876-021-02007-w.
[13]	CHIRIAC S, STANCIU C, SINGEAP AM, et al. Prognostic value of neutrophil-to-lymphocyte ratio in cirrhotic patients with acute-on-chronic liver failure[J]. Turk J Gastroenterol, 2020, 31(12): 868-876. DOI: 10.5152/tjg.2020.19838.
[14]	JIE Y, GONG J, XIAO C, et al. Low platelet to white blood cell ratio indicates poor prognosis for acute-on-chronic liver failure[J]. Biomed Res Int, 2018, 2018: 7394904. DOI: 10.1155/2018/7394904.
[15]	YANG L, WU T, LI J, et al. Artificial liver treatment improves survival in patients with hepatitis B virus-related acute-on-chronic liver failure: A case-control matched analysis[J]. Hepatol Res, 2020, 50(6): 656-670. DOI: 10.1111/hepr.13497.
[16]	LIU H, ZHANG Q, LIU L, et al. Effect of artificial liver support system on short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Artif Organs, 2020, 44(10): E434-E447. DOI: 10.1111/aor.13710.
[17]	GUO X, WU F, GUO W, et al. Comparison of plasma exchange, double plasma molecular adsorption system, and their combination in treating acute-on-chronic liver failure[J]. J Int Med Res, 2020, 48(6): 300060520932053. DOI: 10.1177/0300060520932053.
[18]	CHEN JJ, HUANG JR, YANG Q, et al. Plasma exchange-centered artificial liver support system in hepatitis B virus-related acute-on-chronic liver failure: a nationwide prospective multicenter study in China[J]. Hepatobiliary Pancreat Dis Int, 2016, 15(3): 275-281. DOI: 10.1016/s1499-3872(16)60084-x.
[19]	CHEN YY, LI H, XU BY, et al. Plasma exchange-based non-bioartificial liver support system improves the short-term outcomes of patients with hepatitis B virus-associated acute-on-chronic liver failure: A multicenter prospective cohort study[J]. Front Med (Lausanne), 2021, 8: 779744. DOI: 10.3389/fmed.2021.779744.
[20]	TAN ZQ. Analysis of risk factors for the prognosis of patients with hepatitis B-related acute-on-chronic liver failure[D]. Nanchang: Nanchang University, 2021. 谭志强. 乙型肝炎相关慢加急性肝衰竭患者预后的危险因素分析[D]. 南昌: 南昌大学, 2021.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	童凯，罗红兰. 洛铂通过PERK/eIF2α/ATF4/CHOP信号通路调节肺癌细胞A549的作用机制. 世界临床药物. 2023(08): 805-812 .
2.	李中华，李晓冰，陈建卫，刘晓宇，黄晓峰. 90例肝细胞肝癌患者洛铂混合碘油、微球栓塞治疗的近期疗效观察. 中国疗养医学. 2020(09): 981-983 .
3.	马颖，马明，马玲. 阿司匹林抑制肝癌细胞HepG2增殖及其机制研究. 西北药学杂志. 2020(06): 860-863 .
4.	徐志诚，陈晓宁，李春海，王晓东，李准. miR-21对肝癌细胞Keap-1/Nrf2通路的调控作用分析. 临床和实验医学杂志. 2019(11): 1141-1144 .
5.	曾琼瑶，张文静，张昱，郭强. 肉桂油活性成分(E)-肉桂醛对结肠癌细胞增殖与凋亡的影响. 中国临床药理学与治疗学. 2019(09): 997-1001 .
6.	卢雄，张欢，邹金花，李海庆. 探讨洛铂在原发性肝癌TACE治疗后白细胞升高的意义. 世界最新医学信息文摘. 2019(92): 163+165 .
7.	任勇军，闵旭立，徐浩，刘帆，陈智粮，贺颖. 洛铂联合表柔比星化疗栓塞治疗原发性肝细胞癌的疗效. 医学信息. 2019(24): 43-46 .

Other cited types(3)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (544) PDF downloads(65)

Clinical efficacy of low-dose plasma exchange combined with double plasma molecular absorption system/hemoperfusion in treatment of acute-on-chronic liver failure

DOI: 10.3969/j.issn.1001-5256.2022.11.017